Henrik J Ditzel

List of Publications by Year
in descending order

167	7,312	57681	78623
papers	citations	46 h-index	77 g-index

173	173	173	13266
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ZBED1 Regulates Genes Important for Multiple Biological Processes of the Placenta. Genes, 2022, 13, 133.	1.0	2
2	Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination. Cancer Cell, 2022, 40, 338-339.	7.7	22
3	Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models. Frontiers in Oncology, 2022, 12, 818437.	1.3	7
4	How to increase value and reduce waste in research: initial experiences of applying Lean thinking and visual management in research leadership. BMJ Open, 2022, 12, e058179.	0.8	3
5	Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer. Cancer Cell, 2022, 40, 800-801.	7.7	10
6	Hypoxia induces HIF1Î±-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nature Communications, 2022, 13, .	5.8	48
7	Signaling pathways essential for triple-negative breast cancer stem-like cells. Stem Cells, 2021, 39, 133-143.	1.4	26
8	Non-covalent Encapsulation of siRNA with Cell-Penetrating Peptides. Methods in Molecular Biology, 2021, 2282, 353-376.	0.4	1
9	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Npj Breast Cancer, 2021, 7, 2.	2.3	7
10	Evaluation of siRNA Stability and Interaction with Serum Components Using an Agarose Gel-Based Single-Molecule FRET Labeling Method. Methods in Molecular Biology, 2021, 2282, 43-56.	0.4	1
11	HMGA2 as a Critical Regulator in Cancer Development. Genes, 2021, 12, 269.	1.0	91
12	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Research, 2021, 23, 26.	2.2	19
13	MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy. Life Sciences, 2021, 276, 119431.	2.0	32
14	Deleted in malignant brain tumor 1 genetic variation confers urinary tract infection risk in children and mice. Clinical and Translational Medicine, 2021, 11, e477.	1.7	5
15	Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes. Molecular Oncology, 2021, 15, 3299-3316.	2.1	5
16	Abstract 1415: Triple combination targeting ER, CDK4/6, and PI3K inhibits tumor growth in ER+ breast cancer resistant to combined fulvestrant and CDK4/6 or PI3K inhibitor. , 2021, , .		3
17	Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. Npj Precision Oncology, 2021, 5, 65.	2.3	20
18	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nature Communications, 2021, 12, 5112.	5.8	38

#	Article	IF	Citations
19	Antibody and TÂcell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell, 2021, 39, 1034-1036.	7.7	132
20	DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma. Molecular Cancer, 2021, 20, 108.	7.9	18
21	HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer. Cancers, 2021, 13, 5197.	1.7	11
22	Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2â^' Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. Cancers, 2021, 13, 5397.	1.7	7
23	ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy. Acta OncolÃ³gica, 2020, 59, 40-47.	0.8	3
24	EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy. Nature Communications, 2020, 11, 5878.	5.8	29
25	Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. Expert Opinion on Therapeutic Targets, 2020, 24, 255-265.	1.5	30
26	Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors. Cell Death and Disease, 2020, 11, 110.	2.7	27
27	Simple FRET Electrophoresis Method for Precise and Dynamic Evaluation of Serum siRNA Stability. ACS Medicinal Chemistry Letters, 2020, 11, 195-202.	1.3	4
28	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology, 2020, 15, 973-999.	0.5	66
29	The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors. Frontiers in Oncology, 2020, 10, 584024.	1.3	7
30	Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death and Differentiation, 2019, 26, 276-290.	5.0	69
31	CYPOR is a novel and independent prognostic biomarker of recurrenceâ€free survival in tripleâ€negative breast cancer patients. International Journal of Cancer, 2019, 144, 631-640.	2.3	17
32	A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. Cell Death and Disease, 2019, 10, 841.	2.7	4
33	Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome. Cell Reports, 2019, 27, 3927-3938.e6.	2.9	110
34	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism, 2019, 7, 6.	2.4	51
35	Remodeling and destabilization of chromosome 1 pericentromeric heterochromatin by SSX proteins. Nucleic Acids Research, 2019, 47, 6668-6684.	6.5	18
36	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clinical Cancer Research, 2019, 25, 7046-7057.	3.2	56

#	Article	IF	Citations
37	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight, 2019, 4, .	2.3	42
38	Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nature Communications, 2018, 9, 785.	5.8	29
39	Correlation between circulating cellâ€free <scp>PIK</scp>3<scp>CA</scp> tumor <scp>DNA</scp> levels and treatment response in patients with <scp>PIK</scp>3<scp>CA</scp>â€mutated metastatic breast cancer. Molecular Oncology, 2018, 12, 925-935.	2.1	57
40	Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions. Molecular Cancer Research, 2018, 16, 417-427.	1.5	22
41	One-step FPLC-size-exclusion chromatography procedure for purification of rDMBT1 6Âkb with increased biological activity. Analytical Biochemistry, 2018, 542, 16-19.	1.1	6
42	Coexisting genomic aberrations associated with lymph node metastasis in breast cancer. Journal of Clinical Investigation, 2018, 128, 2310-2324.	3.9	22
43	KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer. Journal of Experimental Medicine, 2018, 215, 2833-2849.	4.2	33
44	SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Research, 2018, 20, 60.	2.2	36
45	Human cancer evolution in the context of a human immune system in mice. Molecular Oncology, 2018, 12, 1797-1810.	2.1	11
46	Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. OncoImmunology, 2017, 6, e1305531.	2.1	58
47	Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening. Stem Cells, 2017, 35, 1898-1912.	1.4	13
48	De novo pathway-based biomarker identification. Nucleic Acids Research, 2017, 45, e151-e151.	6.5	48
49	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nature Medicine, 2017, 23, 1319-1330.	15.2	116
50	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute, 2017, 109, .	3.0	128
51	On the performance of de novo pathway enrichment. Npj Systems Biology and Applications, 2017, 3, 6.	1.4	51
52	Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery. Molecular Therapy - Nucleic Acids, 2017, 8, 264-276.	2.3	29
53	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications, 2017, 8, 410.	5.8	117
54	Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Oncotarget, 2016, 7, 57239-57253.	0.8	30

#	Article	IF	Citations
55	Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells. Oncotarget, 2016, 7, 39768-39783.	0.8	43
56	Prospective validation of a bloodâ€based 9â€miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography. Molecular Oncology, 2016, 10, 1621-1626.	2.1	19
57	A Simulated Annealing Algorithm for Maximum Common Edge Subgraph Detection in Biological Networks. , 2016, , .		4
58	The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genomics, 2016, 17, 442.	1.2	25
59	High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptorâ€"Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 5514-5526.	3.2	57
60	KeyPathwayMinerWeb: online multi-omics network enrichment. Nucleic Acids Research, 2016, 44, W98-W104.	6.5	45
61	The role of GAGE cancer/testis antigen in metastasis: the jury is still out. BMC Cancer, 2016, 16, 7.	1.1	12
62	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. JAMA Oncology, 2016, 2, 217.	3.4	21
63	Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer. Acta OncolÃ³gica, 2016, 55, 167-177.	0.8	8
64	Robust de novo pathway enrichment with KeyPathwayMiner 5. F1000Research, 2016, 5, 1531.	0.8	30
65	HIF2Î± contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. Oncotarget, 2016, 7, 11238-11250.	0.8	16
66	Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasionin vitroand metastasisin vivo. Oncotarget, 2016, 7, 16773-16792.	0.8	36
67	GAGE Proteins. , 2016, , 1827-1828.		0
68	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget, 2015, 6, 15772-15787.	0.8	265
69	The potential of Src inhibitors. Aging, 2015, 7, 734-735.	1.4	23
70	Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene, 2015, 34, 1919-1927.	2.6	69
71	Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumor Biology, 2015, 36, 4327-4338.	0.8	36
72	Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Molecular Oncology, 2015, 9, 437-449.	2.1	33

#	Article	IF	Citations
73	Selection of LNA-containing DNA aptamers against recombinant human CD73. Molecular BioSystems, 2015, 11, 1260-1270.	2.9	34
74	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1â€“98 trial. Breast Cancer Research and Treatment, 2015, 151, 373-384.	1.1	26
75	<scp>S</scp>100A14 is a novel independent prognostic biomarker in the tripleâ€negative breast cancer subtype. International Journal of Cancer, 2015, 137, 2093-2103.	2.3	19
76	Stromal CD8+ T-cell Densityâ€”A Promising Supplement to TNM Staging in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2635-2643.	3.2	269
77	NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer*. Molecular and Cellular Proteomics, 2015, 14, 2988-2999.	2.5	34
78	IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Communications, 2015, 6, 8746.	5.8	125
79	Detecting Plasma Tumor DNA in Early-Stage Breast Cancerâ€”Letter. Clinical Cancer Research, 2015, 21, 3569-3569.	3.2	3
80	Fyn is an important molecule in cancer pathogenesis and drug resistance. Pharmacological Research, 2015, 100, 250-254.	3.1	101
81	Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Breast Cancer Research and Treatment, 2015, 154, 483-494.	1.1	9
82	Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer. PLoS ONE, 2015, 10, e0134967.	1.1	11
83	miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonizationin vivoand causes significant signaling alterations. Oncotarget, 2015, 6, 29224-29239.	0.8	18
84	Abstract A2-59: Resistance mechanisms to erlotinib in the non-small cell lung cancer cell line, HCC827 examined by RNA-seq. , 2015, , .		0
85	Abstract A2-17: High expression of CDK6 confers resistance to fulvestrant in breast cancer cells and is a potential predictor of fulvestrant treatment failure in estrogen receptor-positive breast cancer. , 2015, , .		0
86	Abstract C10: Quantitative proteomics of formalin-fixed paraffin-embedded, primary triple-negative breast cancer tissues of patients who experienced distant metastasis or no recurrence. , 2015, , .		0
87	Abstract C150: High expression of SNAI2 is associated with the emergence of a highly motile fulvestrant-resistant phenotype and is an indicator of poor response to endocrine treatment in estrogen receptor-positive metastatic breast cancer. , 2015, , .		0
88	SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic Acids Research, 2014, 42, 11433-11446.	6.5	21
89	Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. Leukemia and Lymphoma, 2014, 55, 911-919.	0.6	27
90	Application of proteomics in the study of rodent models of cancer. Proteomics - Clinical Applications, 2014, 8, 640-652.	0.8	8

#	Article	IF	Citations
91	Novel circulating microRNA signature as a potential nonâ€invasive multiâ€marker test in ERâ€positive earlyâ€stage breast cancer: A case control study. Molecular Oncology, 2014, 8, 874-883.	2.1	157
92	Tissue Microarrays in Nonâ€“Small-Cell Lung Cancer: Reliability of Immunohistochemically-Determined Biomarkers. Clinical Lung Cancer, 2014, 15, 222-230.e3.	1.1	13
93	<scp>SSX2</scp>â€4 expression in earlyâ€stage nonâ€small cell lung cancer. Tissue Antigens, 2014, 83, 344-349.	1.0	16
94	Evaluation of the ability of adjuvant tamoxifenâ€benefit gene signatures to predict outcome of hormoneâ€naive estrogen receptorâ€positive breast cancer patients treated with tamoxifen in the advanced setting. Molecular Oncology, 2014, 8, 1679-1689.	2.1	18
95	Elucidation of epithelialâ€“mesenchymal transition-related pathways in a triple-negative breast cancer cell line model by multi-omics interactome analysis. Integrative Biology (United Kingdom), 2014, 6, 1058-1068.	0.6	17
96	KeyPathwayMiner 4.0: condition-specific pathway analysis by combining multiple omics studies and networks with Cytoscape. BMC Systems Biology, 2014, 8, 99.	3.0	59
97	Alterations in Circulating miRNA Levels following Early-Stage Estrogen Receptor-Positive Breast Cancer Resection in Post-Menopausal Women. PLoS ONE, 2014, 9, e101950.	1.1	26
98	TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression. Tumor Biology, 2013, 34, 3839-3851.	0.8	18
99	Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. British Journal of Haematology, 2013, 161, 373-382.	1.2	17
100	Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells. Journal of Immunology, 2013, 191, 4165-4173.	0.4	114
101	Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer, 2013, 13, 466.	1.1	32
102	Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. Acta OncolÃ³gica, 2013, 52, 82-90.	0.8	14
103	Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis. Leukemia and Lymphoma, 2013, 54, 425-427.	0.6	10
104	Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Research, 2013, 15, R119.	2.2	46
105	Decorin is downâ€regulated in multiple myeloma and <scp>MGUS</scp> bone marrow plasma and inhibits <scp>HGF</scp>â€induced myeloma plasma cell viability and migration. European Journal of Haematology, 2013, 91, 196-200.	1.1	25
106	Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG Study. PLoS ONE, 2013, 8, e54078.	1.1	11
107	CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. Journal of the National Cancer Institute, 2012, 104, 441-451.	3.0	316
108	Lipids, curvature stress, and the action of lipid prodrugs: Free fatty acids and lysolipid enhancement of drug transport across liposomal membranes. Biochimie, 2012, 94, 2-10.	1.3	42

#	Article	IF	Citations
109	Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study. PLoS ONE, 2012, 7, e36170.	1.1	53
110	GAGE Cancer-Germline Antigens Are Recruited to the Nuclear Envelope by Germ Cell-Less (GCL). PLoS ONE, 2012, 7, e45819.	1.1	14
111	Functional Heterogeneity within the CD44 High Human Breast Cancer Stem Cell-Like Compartment Reveals a Gene Signature Predictive of Distant Metastasis. Molecular Medicine, 2012, 18, 1109-1121.	1.9	73
112	Quantitative proteomics of primary tumors with varying metastatic capabilities using stable isotopeâ€labeled proteins of multiple histogenic origins. Proteomics, 2012, 12, 2139-2148.	1.3	19
113	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Research and Treatment, 2012, 134, 207-217.	1.1	94
114	Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma.. Blood, 2012, 120, 2922-2922.	0.6	0
115	Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma. Blood, 2012, 120, 3977-3977.	0.6	0
116	Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. Cancer Genomics and Proteomics, 2012, 9, 265-73.	1.0	15
117	Analytical variables influencing the performance of a miRNA based laboratory assay for prediction of relapse in stage I non-small cell lung cancer (NSCLC). BMC Research Notes, 2011, 4, 424.	0.6	10
118	Plasma Membrane Proteomics and Its Application in Clinical Cancer Biomarker Discovery. Molecular and Cellular Proteomics, 2010, 9, 1369-1382.	2.5	142
119	Expression, purification and characterization of the cancer-germline antigen GAGE12I: A candidate for cancer immunotherapy. Protein Expression and Purification, 2010, 73, 217-222.	0.6	4
120	Discriminating Isogenic Cancer Cells and Identifying Altered Unsaturated Fatty Acid Content as Associated with Metastasis Status, Using K-Means Clustering and Partial Least Squares-Discriminant Analysis of Raman Maps. Analytical Chemistry, 2010, 82, 2797-2802.	3.2	86
121	Effect of free fatty acids and lysolipids on cellular uptake of doxorubicin in human breast cancer cell lines. Anti-Cancer Drugs, 2010, 21, 674-677.	0.7	16
122	Autoantibodies against C1q in Systemic Lupus Erythematosus Are Antigen-Driven. Journal of Immunology, 2009, 183, 8225-8231.	0.4	50
123	Metastasis-related Plasma Membrane Proteins of Human Breast Cancer Cells Identified by Comparative Quantitative Mass Spectrometry. Molecular and Cellular Proteomics, 2009, 8, 1436-1449.	2.5	113
124	Scanning the Cell Surface Proteome of Cancer Cells and Identification of Metastasis-Associated Proteins Using a Subtractive Immunization Strategy. Journal of Proteome Research, 2009, 8, 5048-5059.	1.8	12
125	Epigenetic Modulation of Cancer-Germline Antigen Gene Expression in Tumorigenic Human Mesenchymal Stem Cells. American Journal of Pathology, 2009, 175, 314-323.	1.9	24
126	Efficient Isolation and Quantitative Proteomic Analysis of Cancer Cell Plasma Membrane Proteins for Identification of Metastasis-Associated Cell Surface Markers. Journal of Proteome Research, 2009, 8, 3078-3090.	1.8	99

#	Article	IF	Citations
127	Affinity Isolation of Antigen-Specific Circulating B Cells for Generation of Phage Display-Derived Human Monoclonal Antibodies. Methods in Molecular Biology, 2009, 562, 37-43.	0.4	4
128	Identification of the Specificity of Isolated Phage Display Single-Chain Antibodies Using Yeast Two-Hybrid Screens. Methods in Molecular Biology, 2009, 562, 165-176.	0.4	4
129	An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens, 2008, 71, 187-192.	1.0	57
130	Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer, 2008, 8, 20.	1.1	89
131	Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. Human Reproduction, 2008, 23, 2194-2201.	0.4	52
132	Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer. Nature Clinical Practice Oncology, 2008, 5, 376-377.	4.3	1
133	GAGE Proteins. , 2008, , 1193-1194.		0
134	Phage Displayâ€“Derived Human Monoclonal Antibodies Isolated by Binding to the Surface of Live Primary Breast Cancer Cells Recognize GRP78. Cancer Research, 2007, 67, 9507-9517.	0.4	64
135	MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Human Reproduction, 2007, 22, 953-960.	0.4	61
136	Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI). Biochemical and Biophysical Research Communications, 2006, 349, 838-845.	1.0	20
137	Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. British Journal of Cancer, 2006, 94, 1864-1873.	2.9	54
138	Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs. Journal of Immunological Methods, 2005, 297, 187-201.	0.6	13
139	Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2005, 64, 743-749.	0.5	38
140	Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 395-399.	6.7	70
141	A Human Single-Chain Antibody Specific for Integrin Î±3Î²1 Capable of Cell Internalization and Delivery of Antitumor Agents. Chemistry and Biology, 2004, 11, 897-906.	6.2	31
142	Molecular Analysis of the Human Autoantibody Response to Î±-Fodrin in SjÃ¶gren's Syndrome Reveals Novel Apoptosis-Induced Specificity. American Journal of Pathology, 2004, 165, 53-61.	1.9	31
143	The K/BxN mouse: a model of human inflammatory arthritis. Trends in Molecular Medicine, 2004, 10, 40-45.	3.5	105
144	Identification of talin head domain as an immunodominant epitope of the antiplatelet antibody response in patients with HIV-1-associated thrombocytopenia. Blood, 2004, 104, 4054-4062.	0.6	13

#	Article	IF	Citations
145	Dissecting the Cellular Functions of Annexin XI Using Recombinant Human Annexin XI-specific Autoantibodies Cloned by Phage Display. Journal of Biological Chemistry, 2003, 278, 33120-33126.	1.6	26
146	Rescue of a Broader Range of Antibody Specificities Using an Epitope-Masking Strategy. , 2002, 178, 179-186.		8
147	Translocation of an Intracellular Antigen to the Surface of Medullary Breast Cancer Cells Early in Apoptosis Allows for an Antigen-Driven Antibody Response Elicited by Tumor-Infiltrating B Cells. Journal of Immunology, 2002, 169, 2701-2711.	0.4	73
148	Cancer-associated Cleavage of Cytokeratin 8/18 Heterotypic Complexes Exposes a Neoepitope in Human Adenocarcinomas. Journal of Biological Chemistry, 2002, 277, 21712-21722.	1.6	34
149	A cell-penetrating peptide from a novel pVIIâ€“pIX phage-displayed random peptide library. Bioorganic and Medicinal Chemistry, 2002, 10, 4057-4065.	1.4	81
150	Response to 'Autoantibodies to GPI and creatine kinase in RA' and 'Few human autoimmune sera detect GPI'. Nature Immunology, 2002, 3, 412-413.	7.0	19
151	Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nature Immunology, 2001, 2, 746-753.	7.0	187
152	The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12659-12664.	3.3	157
153	Human Antibodies in Cancer and Autoimmune Disease. Immunologic Research, 2000, 21, 185-194.	1.3	17
154	Antibodies in Human Infectious Disease. Immunologic Research, 2000, 21, 265-278.	1.3	11
155	Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2â€“Mbp 85â€“99 Complex. Journal of Experimental Medicine, 2000, 191, 1395-1412.	4.2	186
156	Human monoclonal antibodies: A tool for cancer detection in vivo. Apmis, 1999, 107, 5-42.	0.9	2
157	The CCR5 receptor acts as an alloantigen in CCR5Â32 homozygous individuals: Identification of chemokineand HIV-1-blocking human antibodies. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 5241-5245.	3.3	43
158	Simian Immunodeficiency Virus (SIV) Envelope-Specific Fabs with High-Level Homologous Neutralizing Activity: Recovery from a Long-Term-Nonprogressor SIV-Infected Macaque. Journal of Virology, 1998, 72, 585-592.	1.5	39
159	Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity. Journal of Virology, 1998, 72, 3512-3519.	1.5	182
160	Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8110-8115.	3.3	27
161	Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries 1 1Edited by F. E. Cohen. Journal of Molecular Biology, 1997, 267, 684-695.	2.0	57
162	Pilot scale purification of human monoclonal IgM (COU-1) for clinical trials. Journal of Immunological Methods, 1997, 205, 11-17.	0.6	24

#	Article	IF	Citations
163	Human Antibody Responses to HIV Type 1 Glycoprotein 41 Cloned in Phage Display Libraries Suggest Three Major Epitopes Are Recognized and Give Evidence for Conserved Antibody Motifs in Antigen Binding. AIDS Research and Human Retroviruses, 1996, 12, 911-924.	0.5	81
164	Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. Aids, 1995, 9, 1-538.	1.0	135
165	Human autoantibody recognition of DNA.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2529-2533.	3.3	124
166	Human monoclonal Fab fragments specific for viral antigens from combinatorial IgA libraries. Immunotechnology: an International Journal of Immunological Engineering, 1995, 1, 21-28.	2.4	15
167	Cholesterol Biosynthesis Is a Key Feature of Cancer Stem Cells as Revealed by Proteomic Comparison of Breast Cancer Tissue, Corresponding PDXs and Mammospheres. SSRN Electronic Journal, 0, , .	0.4	0